Shopping Cart
- Remove All
- Your shopping cart is currently empty
IAXO-102 is a TLR4 antagonist that negatively regulates TLR4 signaling by inhibiting MAPK and p65 NF-κB phosphorylation, as well as the expression of TLR4-dependent proinflammatory proteins. It also prevents the development of experimental abdominal aortic aneurysm.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $89 | In Stock | |
2 mg | $136 | In Stock | |
5 mg | $263 | In Stock | |
10 mg | $422 | In Stock | |
25 mg | $689 | In Stock | |
50 mg | $981 | In Stock | |
100 mg | $1,350 | In Stock |
Description | IAXO-102 is a TLR4 antagonist that negatively regulates TLR4 signaling by inhibiting MAPK and p65 NF-κB phosphorylation, as well as the expression of TLR4-dependent proinflammatory proteins. It also prevents the development of experimental abdominal aortic aneurysm. |
In vitro | IAXO-102 (10 μM, for 17 hours) suppresses LPS induced pro-inflammatory proteins MCP-1 and IL-8 production in HUVEC. IAXO-102 (1-10 μM, for 2 hours) inhibits MAPK and p65 NF-κB phosphorylation in human umbilical vein endothelial (HUVEC) cells. |
In vivo | IAXO-102 (3 mg/kg/day, s.c. for 28 days) significantly retards Angiotensin II-induced increase in aortic diameter in mice. |
Molecular Weight | 585.94 |
Formula | C35H71NO5 |
Cas No. | 1115270-63-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | Ethanol: 45 mg/mL (76.8 mM), Sonication is recommended. DMSO: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
Ethanol
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.